Drugs / Brazilian Green Propolis Extract
Brazilian Green Propolis Extract
also known as
EPP-AF
Traditional medicine (herbal / TCM) targets ACE2, PAK1, TMPRSS2 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04480593 | Jun → Aug 2020 | COVID-19 | D'Or Institute for Research and Education | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brazilian Green Propolis Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04480593 ↗ |
| Known as | EPP-AF | “Brazilian Green Propolis Extract (EPP-AF)” NCT04480593 ↗ |
| Action | Inhibit | “Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways” NCT04480593 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Propolis has been employed extensively in many cultures since ancient times as antiseptic, wound healing, anti-pyretic and others due to its biological and pharmacological properties” PMID 31442620 ↗ Aug 2019 |
| Route | Oral | “Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.” NCT04480593 ↗ |
| Route | Other | “Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.” NCT04480593 ↗ |
| Target | ACE2 | “Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways” NCT04480593 ↗ |
| Target | PAK1 | “Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways” NCT04480593 ↗ |
| Target | TMPRSS2 | “Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways” NCT04480593 ↗ |